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Summary (156 words) 141 
Earlier detection of relapse following primary surgery for non-small cell lung cancer and the 142 
characterization of emerging subclones seeding metastatic sites might offer new therapeutic 143 
approaches to limit tumor recurrence. The potential to non-invasively track tumor evolutionary 144 
dynamics in ctDNA of early-stage lung cancer is not established. Here we conduct a patient-145 
specific approach to ctDNA profiling in the first 100 lung TRACERx (TRAcking Cancer 146 
Evolution through therapy (Rx)) study participants, including one patient co-recruited to the 147 
PEACE (Posthumous Evaluation of Advanced Cancer Environment) post-mortem study. We 148 
identify independent predictors of ctDNA release in early-stage non-small cell lung cancer and 149 
perform tumor volume limit of detection analyses. Through blinded profiling of post-operative 150 
plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients 151 
destined to experience recurrence of their lung cancer. Finally, we show that phylogenetic 152 
ctDNA profiling tracks the subclonal nature of lung cancer relapse and metastases, providing 153 
a new approach for ctDNA driven therapeutic studies 154 
 155 
 156 
Main text  157 
Lung cancer is the leading cause of cancer death worldwide1-2. Established metastatic non-158 
small cell lung cancer (NSCLC) cannot be cured with systemic chemotherapy. Yet clinical 159 
studies have shown a 5% benefit of post-operative (adjuvant) chemotherapy on overall 160 
survival3. This modest survival benefit may reflect a vulnerability of treating low volume 161 
disease within the context of reduced intra-tumor heterogeneity4. Improving adjuvant treatment 162 
of lung cancer could improve cure rates. However, achieving this objective will require the 163 
development of a diagnostic platform capable of identifying, monitoring and genomically 164 
characterizing recurring or residual disease early. This would create a therapeutic setting where 165 
only patients destined to recur would receive treatment, where intervention could be directed 166 
to the evolving tumor subclone seeding metastatic recurrence guided by clinical trials powered 167 
to determine treatment effect within smaller patient cohorts.  168 
Circulating tumor DNA (ctDNA) detection in plasma has been shown in breast5,6 and colorectal 169 
cancer7 to detect minimal residual disease in the adjuvant setting and identify patients destined 170 
to relapse post-operatively in advance of established clinical parameters. Here, we report a 171 
bespoke multiplex-PCR NGS approach to ctDNA profiling within the context of the 172 
prospective tumor evolutionary NSCLC study TRACERx. We address determinants of ctDNA 173 
detection in early-stage NSCLC and investigate the ability of ctDNA to identify and 174 
genomically characterize, at subclone resolution, post-operative NSCLC relapse using a tumor 175 
phylogenetic framework.   176 
Phylogenetic ctDNA profiling 177 
The TRACERx study monitors the clonal evolution of NSCLC from diagnosis through to 178 
relapse and death8. Using multi-region exome sequencing (M-Seq) derived tumor phylogenetic 179 
trees developed through prospective analysis of the 100 patient TRACERx cohort, we 180 
conducted a phylogenetic approach to ctDNA profiling in early stage NSCLC (Fig. 1). Bespoke 181 
multiplex-PCR assay-panels were synthesised for each patient, targeting clonal and subclonal 182 
single nucleotide variants (SNVs) selected to track phylogenetic tumor branches in plasma (Fig 183 
1.). Analytical validation of the multiplex-PCR NGS platform demonstrated a sensitivity of 184 
above 99% for the detection of SNVs at frequencies above 0.1% and the specificity of detecting 185 
a single SNV was 99.6% (Extended Data Fig 1a). At least two SNVs were detected in ctDNA 186 
from each NSCLC analyzed in our published discovery cohort data9, demonstrating biological 187 
sensitivity of a two SNV threshold for ctDNA detection in early-stage NSCLC. Therefore, we 188 
prospectively selected a threshold of two detected SNVs for calling a sample ctDNA positive 189 
for validation within this study - to minimize type I error in a platform testing up to 30 tumour-190 
specific SNVs per time-point in a single patient (see Extended Data Fig 1b for justification). 191 
Cross-platform validation was performed in 28 patients with M-Seq confirmed SNV(s) within 192 
one or more hotspots targeted by a generic multiplex PCR-NGS panel (Extended Table 1a-b, 193 
Supplementary Table 1). All 18 bespoke-panel ctDNA negative patients had no tumor SNVs 194 
detectable in plasma pre-operatively by the generic panel supporting biological specificity of 195 
the targeted approach, 7 of 10 bespoke-panel ctDNA positive patients had tumor SNVs 196 
detected in plasma by the generic panel (Extended Table 1a-b). 197 
Determinants of ctDNA detection in NSCLC  198 
We sought to identify clinicopathological determinants of ctDNA detection in early-stage 199 
NSCLC by profiling pre-operative plasma samples in 96 of 100 TRACERx patients (cohort, 200 
sample characteristics Extended Table 2a-c, Supplementary Table 2). It was not possible to 201 
analyze samples from four patients (see Extended Data Fig 2a for details). Individual patient 202 
assay-panels were designed to target a median of 18 SNVs (range 10 to 22) comprising a 203 
median of 11 clonal SNVs (range 2 to 20) and a median of 6 subclonal SNVs (range 0 to 16) 204 
(Extended Data Fig 2b).  205 
At least two SNVs were detected in ctDNA pre-operatively in 46 of 96 (48%) early-stage 206 
NSCLCs, a single SNV was detected in 12 additional cases (Fig 2a). Centrally reviewed 207 
pathological data revealed that ctDNA detection was associated with histological subtype: 97% 208 
(30/31) of lung squamous cell carcinomas (LUSCs) and 71% (5 of 7) of other NSCLC subtypes 209 
were ctDNA positive, compared with 19% (11/58) of lung adenocarcinomas (LUADs) (Fig 210 
2a). ctDNA detection stratified by TNM stage revealed that 94% (16 of 17) of stage I LUSCs 211 
were detected compared with 13% (5 of 39) of stage I LUADs (Extended Data Fig 3a). 212 
Passive release of ctDNA into the circulation may be associated with apoptosis and necrosis10. 213 
As expected11, LUSCs were significantly more necrotic than LUADs and ctDNA positive 214 
LUADs formed a sub-group of more necrotic tumors compared with ctDNA negative LUADs 215 
(Extended Data Fig 3b). Necrosis, lymph node involvement, lymphovascular invasion, 216 
pathological tumor size, Ki67 labelling indices, non-adenocarcinoma histology and total cell-217 
free DNA input predicted ctDNA detection in univariable analyses (Extended Data Fig 3c). 218 
Multivariable analysis revealed non-adenocarcinoma histology, the presence of lympho-219 
vascular invasion and high Ki67 proliferation index as independent predictors of ctDNA 220 
detection (Extended Data Fig 3c). Since FDG-avidity on positron emission tomography (PET) 221 
scans correlates with proliferative indices in early-stage NSCLC12,13, we investigated tumor 222 
PET FDG-avidity and ctDNA detection. PET FDG-avidity predicted ctDNA detection (area 223 
under curve = 0.84, P<0.001, n=92) (Extended Data Fig 3d). Within LUADs, common driver 224 
events in KRAS, EGFR or TP53 were not associated with ctDNA detection (Extended Data 225 
Fig 3e).  226 
We analyzed the distribution of clonal and subclonal SNVs in ctDNA positive patients. Clonal 227 
SNVs were detected in all 46 ctDNA positive patients; a median of 94% (range 11% to 100%) 228 
of clonal SNVs targeted by assay-panels were detected in ctDNA. 40 of 46 ctDNA positive 229 
patients had subclonal SNVs targeted by assay-panels and subclonal SNVs were detected in 27 230 
(68%) of these patients. A median of 27% (range 0% to 91%) of targeted subclonal SNVs were 231 
detected in ctDNA positive patients (Figure 2b). The mean plasma variant allele frequency 232 
(VAF) of clonal SNVs was significantly higher than that of subclonal SNVs (Extended Data 233 
Fig 4a) (within patient comparison, Wilcoxon signed-rank test, P<0.001, n=27, 234 
Supplementary Table 3) supporting the use of clonal alterations as a more sensitive method 235 
of ctDNA detection than subclonal alterations9,14.  236 
In ctDNA positive patients, macroscopic tumor size correlated with mean clonal plasma VAF 237 
(Spearman’s Rho = 0.405, P=0.005, n=46) (Extended Data Fig 4b). CT scan volumetric 238 
analyses were available in 38 of 46 ctDNA positive patients (see Extended Data Fig 4c). 239 
Tumor volume correlated with mean clonal plasma VAF (Fig 3a, Spearman’s Rho = 0.61, 240 
P<0.001, n=38). A linear relationship between log- transformed volume and mean clonal VAF 241 
values was observed (Fig 3a). The line of best fit applied to our data was consistent with the 242 
line fitted to NSCLC volumetric data and ctDNA plasma VAFs reported in previously 243 
published work15 (Extended Data Fig 4d). Linear modelling based on the TRACERx data 244 
approximated that a primary tumor volume of 11cm3 would result in a mean clonal plasma 245 
VAF of 0.1% (Figure 3b). We multiplied tumor purity by tumor volume to control for stromal 246 
contamination and determine cancer cell volume (Extended Data Fig 4e). On the assumption 247 
that 1cm3 of effective tumor contains 9.4 x 107 cells we approximated that a plasma VAF of 248 
0.1% corresponds to a tumor burden of 326 million malignant cells (Extended Data Fig 4f). 249 
To investigate predictors of subclone detection we mapped detected subclonal SNVs back to 250 
M-seq derived tumor phylogenetic trees. 35 of 57 (61%) shared subclones (identified in more 251 
than one tumor region through M-Seq analysis) were identified in ctDNA, compared with 26 252 
of 80 (33%) private subclones (detected in a single tumor region only) (Extended Data Fig 253 
4g). This suggested subclone volume influences subclonal ctDNA detection. We estimated 254 
subclone volume based on mean regional subclone cancer cell fraction (CCF) and cancer cell 255 
volume. Detected subclonal SNVs mapped to subclones with significantly higher estimated 256 
volumes than subclones containing undetected SNVs (Figure 3c) and subclone volume 257 
correlated with subclonal SNV plasma VAF (Figure 3d).  258 
Detecting and characterizing NSCLC relapse 259 
The longitudinal phase of the study aimed to determine if ctDNA profiling with patient-specific 260 
assay panels could detect and characterize the branched subclone(s) seeding NSCLC relapse. 261 
Pre- and post-surgical plasma ctDNA profiling was performed blinded to relapse status in a 262 
sub-group of 24 patients (cohort characteristics, Extended Table 2d-e). This included relapse 263 
free patients who had been followed-up for a median of 775 days (range 688 to 945 days, n=10) 264 
and confirmed NSCLC relapse cases (n=14) (cohort design, Extended Data Fig 2c). PCR 265 
assays were added to panels in this phase of the study to optimize sensitivity in LUADs. A 266 
median of 18.5 SNVs (range 12 to 20) were targeted by LUSC assay-panels and a median of 267 
28 SNVs (range 25 to 30) were targeted by LUAD assay-panels (Extended Data Fig 2d-e).  268 
Patients were followed up with three to six monthly clinical assessment and chest radiographs. 269 
At least 2 SNVs were detected in 13 of 14 (93%) patients with confirmed NSCLC relapse prior 270 
to, or at, clinical diagnosis of relapse and detected in 1 of 10 (10%) patients (CRUK0013) with 271 
no clinical evidence of NSCLC relapse (Fig 4a-k, Extended Data Fig 5a-n). Excluding a 272 
single case where no post-operative plasma was taken prior to clinical relapse (CRUK0041) 273 
the median interval between ctDNA detection and NSCLC relapse confirmed on clinically 274 
indicated CT imaging (lead-time) was 70 days (range 10 to 346 days). Four of 13 relapse cases 275 
exhibited lead-times of more than six months (Fig 4a-d).  In two cases ctDNA detection 276 
preceded CT imaging inconclusive for NSCLC relapse by 347 days (Fig 4a) and 260 days (Fig 277 
4d).  Post-operative ctDNA profiling reflected adjuvant chemotherapy resistance; CRUK0004, 278 
CRUK0080 and CRUK0062 had detectable ctDNA in plasma within 30 days of surgery. The 279 
number of detectable SNVs increased in all cases despite adjuvant chemotherapy with disease 280 
recurring within 1 year of surgery (Fig. 4a-c). In contrast, CRUK0013 had 20 SNVs detectable 281 
in ctDNA 72 hours after surgery and 13 SNVs detectable prior to adjuvant chemotherapy (Fig 282 
4e). 51 days following completion of adjuvant treatment, no SNVs were detectable. Two 283 
further plasma samples were profiled for this patient at day 457 and 667; ctDNA remained 284 
undetectable and the patient remains relapse free 688 days post-surgery (Fig 4e). ctDNA 285 
profiling detected intracerebral relapse; CRUK0029 had a pre-operative PET scan performed 286 
50 days prior to surgery demonstrating normal cerebral appearances. Mean clonal plasma VAF 287 
of detected SNVs remained above 1% 30 days post-surgery, 54 days post-operatively the 288 
patient was confirmed to have intracerebral metastasis (Fig 4f).  289 
We sought to resolve subclonal evolutionary-dynamics associated with NSCLC relapse. 290 
Subclonal SNVs displaying plasma VAFs similar to clonal SNVs and mapping to phylogenetic 291 
clusters confined to a single phylogenetic branch, were detected post-operatively in the ctDNA 292 
of four patients who suffered NSCLC relapse (CRUK0004, CRUK0063, CRUK0065 and 293 
CRUK0044) (Fig. 4a,g-i). These findings suggested a relapse process dominated by a subclone 294 
represented in our assay-panel. Notably the subclone implicated by ctDNA as driving the 295 
relapse in the case of CRUK0004 contained an ERRB2 (HER2) amplification event that may 296 
be targetable in NSCLC16. This suggests ctDNA defined subclonal evolution may inform 297 
precision strategies against emerging subclones (Fig. 4a). Relapses involving subclones from 298 
more than one phylogenetic branch were evident in patients CRUK0080, CRUK0062 and 299 
CRUK0041 (Fig 4b-c,j). 300 
Validation of phylogenetic characterization 301 
To validate subclonal ctDNA analyses, data acquired from sequencing metastatic tissue was 302 
interpreted with M-seq primary tumor data (Supplementary Table 4). Patient CRUK0063 303 
suffered para-vertebral relapse of their NSCLC. Post-operative ctDNA analysis revealed the 304 
detection of the same subclonal SNV (OR5D18) on four consecutive occasions over a 231-day 305 
period (Extended Data Fig 6a). The OR5D18 SNV traced back to a subclonal cluster private 306 
to primary tumor region three (Fig 5a). Exome sequencing of CT-guided biopsy tissue acquired 307 
from the para-vertebral metastasis revealed the subclone implicated in the metastatic event by 308 
detection of the OR5D18 SNV in ctDNA gave rise to the metastatic clone. This supported 309 
ctDNA phylogenetic characterization of relapse (Fig 5a). The para-vertebral biopsy contained 310 
88 SNVs not present in the primary tumor including an ARID1A stop-gain driver SNV. Re-311 
examination of primary tumor region M-Seq data with a lower SNV calling threshold revealed 312 
that 16 of 88 SNVs including ARID1A were detectable in primary tumor region three, compared 313 
to a maximum of 2 of 88 in other tumor regions (Extended Data Fig 6b). Since ctDNA 314 
implicated the subclone private to primary tumor region three in the relapse process, these data 315 
suggest that ctDNA profiling can resolve the primary tumor region from which a low frequency 316 
metastatic subclone derives. CRUK0035 developed two liver and one adrenal metastases (Fig 317 
5b). Sequencing of the metastatic liver deposit revealed that only 109 of 149 SNVs classed as 318 
clonal in the primary tumor were detectable in the metastasis. This was suggestive of an 319 
ancestral branching event not resolved through primary M-seq analysis (Figure 5b). Post-320 
operative ctDNA profiling identified clonal SNVs present in the liver metastasis biopsy but 321 
also revealed SNVs representing a subclone from the primary tumor (Extended Data Fig 6c). 322 
This subclone was not present in the metastatic liver deposit (Fig 5b). These data may reflect 323 
ctDNA identified from the non-biopsied metastases suggesting multiple metastatic events. 324 
CRUK0044 suffered a vertebral and right hilar relapse. Post-operatively the same subclonal 325 
SNV (OR10K1), was detected in ctDNA on two occasions 85 days apart (Extended Data Fig 326 
6d). This SNV represented a single subclone detected through sequencing hilar lymph-node 327 
metastatic tissue, supporting ctDNA findings (Fig. 5c). CRUK0041 suffered an intracerebral, 328 
hilar and subcarinal lymph node relapse. Four subclonal SNVs representing both branches of 329 
the tumor phylogenetic tree were detectable in ctDNA at relapse. Concordant with these data, 330 
sequencing of subcarinal metastatic tissue revealed the presence of subclonal SNVs mapping 331 
to both phylogenetic branches (Fig 5d, Extended Data Fig. 6e). Patient CRUK0013 was found 332 
to have lymph-node metastases following primary surgery. Two lymph node metastases were 333 
sampled for exome analysis together with M-seq of the primary tumor. Subclonal SNVs 334 
detected in ctDNA post-operatively mapped to an ancestral subclone (describing a subclone 335 
that existed during the tumor’s evolution) containing a KRAS amplification (Extended Data 336 
Fig 6f, Fig. 5e). This ancestral subclone was present in the primary tumor and sampled lymph-337 
nodes (Fig. 5e). Given the lymph node involvement in this case these findings suggest residual 338 
metastatic lymphadenopathy following surgery that responded to adjuvant chemoradiotherapy 339 
(Fig. 4e) 340 
ctDNA profiling in the metastatic setting 341 
Patient CRUK0063 underwent examination through the PEACE post-mortem study 24 hours 342 
following death. Six tumor regions were sampled from three metastatic sites (thoracic 343 
vertebral, para-aortic and lung metastases). M-Seq data from the six post-mortem tumor 344 
regions (day 857), the para-vertebral relapse biopsy (day 467) and five primary tumor regions 345 
(day 0) were combined to infer the phylogenetic structure of this patient’s NSCLC (Fig 6a). 346 
All seven metastatic tumor regions arose from a single ancestral subclone represented by 347 
phylogenetic cluster 8 (Fig 6b). Six metastatic regions shared a later phylogenetic origin, 348 
phylogenetic cluster 12 (Fig. 6b). The single tumor region that had not arisen from 349 
phylogenetic cluster 12 was sampled from the para-aortic metastasis at autopsy and contained 350 
a private subclone represented by phylogenetic cluster 9 (Fig 6b). The findings could represent 351 
two or more independent metastatic events arising from a single branch of the primary tumor 352 
phylogenetic tree, with ongoing tumor evolution at each metastatic site (Fig 6b). Or a single 353 
metastatic event to the para-aortic site involving the ancestral subclone (phylogenetic cluster 354 
8) prior to evolution of the subclone represented by phylogenetic cluster 9. Followed by 355 
metastatic cross-seeding to para-vertebral and lung sites and ongoing clonal evolution (Fig 6b). 356 
We designed a bespoke ctDNA assay-panel to retrospectively track metastatic subclonal 357 
burden. 20 clonal SNVs and a median of 8 subclonal SNVs (range 4 to 15) in 9 metastatic 358 
subclonal clusters were targeted by the assay-panel (Extended Data Fig 7). Since 103 variants 359 
per time-point were profiled, SNV call thresholds were increased to maintain platform 360 
specificity of more than 99.2% at the 2 SNV ctDNA detection threshold (see Extended 361 
Methods). ctDNA detection occurred at day 340 post-surgery (Fig 6c, Extended Data Fig 7). 362 
At day 466 following clinical-relapse at the thoracic para-vertebral site, 18 of 20 SNVs 363 
mapping to phylogenetic clusters (8,11 and 12) were detected in ctDNA (Fig 6c, Extended 364 
Data Fig 7). These subclonal clusters were shared between six of seven metastatic sites (Fig 365 
6b). A single SNV from a private subclone (phylogenetic cluster 9) was also detectable in 366 
ctDNA at day 466 (Fig 6c, Extended Data Fig 7). This subclone was not identified in the CT 367 
guided para-vertebral biopsy taken at day 467 (Fig 6b). The mean plasma VAF of the 18 SNVs 368 
detected in phylogenetic clusters 11, 8 and 12 reflected their proximity to the clonal cluster 369 
(light blue) in the M-Seq derived phylogenetic tree (Fig 6c). This suggested a tiered burden of 370 
subclonal disease concordant with M-seq phylogenetic inferences (Fig 6a). Mean clonal VAF 371 
fell in response to palliative radiotherapy and chemotherapy but at day 767 increased (Fig 6c). 372 
Single SNVs mapping to phylogenetic clusters 5 and 9 and two SNVs mapping to phylogenetic 373 
cluster 2 were now detectable in ctDNA 90 days before death (Fig 6a-c, Extended Data Fig 374 
7). These phylogenetic clusters represented subclones private to the para-aortic metastases (Fig 375 
6a-b). Consistent with these data significant para-aortic progression was observed at post-376 
mortem compared with most recent CT imaging performed 112 days before death - which 377 
showed no evidence of para-aortic disease. 378 
Discussion 379 
In summary, we find predictors of ctDNA detection in early-stage NSCLC characterized by 380 
non-adenocarcinoma histology, necrosis, increased proliferative indices and lymphovascular 381 
invasion (Fig 2a). Triple negative breast cancers display necrosis17, high proliferative 382 
indices18,19 and are associated with increased ctDNA levels compared with other breast cancer 383 
subtypes6 suggesting extension of observations to other tumor types.  384 
We find a relationship between tumor volume and ctDNA detection. We estimate that a primary 385 
NSCLC tumor with a volume of 11cm3 is required to achieve a ctDNA plasma VAF of 0.1% 386 
(Fig. 3b), a VAF reflecting the optimum sensitivity of most current ctDNA platforms. Low-387 
dose CT lung screening can identify lung nodules with diameters as low as 4mm20. Assuming 388 
a spherical nodule, this would translate to a volume of 0.034cm3 and an approximate plasma 389 
VAF of 1.4 x 10-4 % - at the extreme of detection limits of ctDNA platforms21. Sensitivity of 390 
ctDNA NSCLC screening may therefore be constrained by tumor size using current 391 
technologies. ctDNA release dynamics may alter at disease relapse - in three LUAD cases we 392 
detect no ctDNA pre-operatively, yet detect ctDNA at relapse in the absence of clinically 393 
detectable disease (Fig 4a,d,i).  394 
Targeted ctDNA profiling characterized the subclonal dynamics of relapsing NSCLC. 395 
Limitations to this approach include cost, estimated at $1750 per patient for single region tumor 396 
sequencing with evaluation of five plasma samples and synthesis of bespoke assay-panels 397 
within a clinically relevant timeframe. Adjuvant platinum-based chemotherapy in NSCLC 398 
improves cure rates following surgery in only 5% of patients and 20% patients receiving 399 
chemotherapy experience acute toxicities22. There is an urgent need to increase adjuvant 400 
therapy efficacy and better target its use. Our findings indicate that drug development guided 401 
by ctDNA platforms to identify residual disease, define treatment response and target emerging 402 
subclones in the adjuvant NSCLC setting, with appropriate CLIA validation, are now feasible. 403 
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Figure 1 Phylogenetic ctDNA tracking 
Overview of the study methodology. Multi-region sequencing of Stage I-IIIB non-small cell 
lung cancers was performed through the TRACERx study. Phylogenetic trees were 
constructed. PCR assay-panels were designed targeting clonal and subclonal single 
nucleotide variants to facilitate non-invasive tracking of the patient-specific tumor 
phylogeny. Based on predicted and validated primer compatibility assay-panels were 
combined into multiplex assay-pools containing primers from up to 10 patients. Cell-free 
DNA was extracted from pre and post-operative plasma samples and multiplex-PCR 
performed. This was followed by next generation sequencing of amplicons. Findings were 
integrated with M-Seq exome data to track tumor evolution. 
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 Figure 2 – Clinicopathological predictors of ctDNA detection 
a) Heatmap showing clinicopathological and ctDNA detection data, continuous variables 
quartiled. Raw data and patient IDs in Supplementary Table 1. b) Detection of clonal and 
subclonal single nucleotide variants within 46 patients with two or more single nucleotide 
variants detected in plasma. Histology indicated in panels as LUSC, LUAD and Other. Other 
histology refers to large cell carcinoma (1/1 ctDNA positive), adenosquamous carcinoma (2/3 
ctDNA positive), large cell neuroendocrine carcinoma (1/1 ctDNA positive) and 
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tumor burden at hypothetical clonal VAF intervals ranging from 0.01% to 10% based on 
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 Figure 4 – Post-operative ctDNA detection predicts and characterizes NSCLC relapse – 
2a-k) Longitudinal cell-free DNA profiling. Circulating tumor DNA (ctDNA) detection in 
plasma was defined as the detection of two tumor-specific SNVs. Relapse was based on 
imaging-confirmed NSCLC relapse, imaging was performed as clinically indicated. Detected 
clonal (circles, light blue) and subclonal (triangles, colors indicates different subclones) 
SNVs from each patient-specific assay-panel are plotted on graphs colored by M-Seq derived 
tumor phylogenetic nodes. Mean clonal (blue) and mean subclonal (red) plasma VAF are 
indicated on graphs as connected lines. Pre-operative and relapse M-Seq derived 
phylogenetic trees represented by ctDNA are illustrated above each graph. 
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Figure 5. Re-design of phylogenetic trees to incorporate relapse tissue sequencing data 
to benchmark post-operative ctDNA analyses 
Phylogenetic trees based on mutations found in primary and metastatic tissue (a-d), or 
primary tumor and lymph node biopsies (e). Colored nodes in phylogenetic trees indicate 
cancer clones harboring mutations assayed for in ctDNA, grey indicates a clone not assayed. 
Thick colored bar shows number of assays per sample detected preoperatively and at relapse 
(a-d) or in the absence of relapse, post surgery (e). Thin colored bar shows number of assays 
in total. Colors matches clones on the phylogenetic trees. 
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Figure 6. ctDNA tracking of lethal cancer subclones in CRUK0063 
Sampling and sequencing was performed of one relapse biopsy at day 467 and five metastatic 
tissue samples from three lesions at time of death through the PEACE (Posthumous 
Evaluation of Advanced Cancer Environment) post mortem study. Phylogenetic analysis 
revealed cancer evolution and identified private subclones at each site. a). To-scale 
phylogenetic tree of CRUK0063 including M-seq based on metastatic and primary tumor 
regions. Branch length is proportional to number of mutations in each subclone. Colors 
represents mutation clusters, light blue node representing the clonal cluster. b) Tissue-
specific phylogenetic trees for metastatic lesions, highlighted nodes in color represents 
mutation clusters found at each site and assayed for in ctDNA. Open circles represents 
mutation clusters not detected at any time in ctDNA. c) Tracking plot of identified subclones 
in ctDNA, showing mean VAF of identified subclones. Size of dots indicates number of 
assays detected. Colors corresponds to mutation clusters and matches panels a and b. Tiered 
burden of subclonal disease can be observed, with clusters representing earlier cancer 
subclones present at higher VAF, likely reflecting a larger cancer burden carrying shared 
relative to private mutations. 
 
 
